Targeting Sclerostin in Postmenopausal Osteoporosis: Focus on Romosozumab and Blosozumab.

about

Targeting Sclerostin in Postmenopausal Osteoporosis: Focus on Romosozumab and Blosozumab.

Item

http://www.wikidata.org/entity/Q48088703

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Targeting Sclerostin in Postmenopausal Osteoporosis: Focus on Romosozumab and Blosozumab.

@en

Targeting Sclerostin in Postmenopausal Osteoporosis: Focus on Romosozumab and Blosozumab.

@nl

type

Item

label

Targeting Sclerostin in Postmenopausal Osteoporosis: Focus on Romosozumab and Blosozumab.

@en

Targeting Sclerostin in Postmenopausal Osteoporosis: Focus on Romosozumab and Blosozumab.

@nl

prefLabel

Targeting Sclerostin in Postmenopausal Osteoporosis: Focus on Romosozumab and Blosozumab.

@en

Targeting Sclerostin in Postmenopausal Osteoporosis: Focus on Romosozumab and Blosozumab.

@nl

P1476

Targeting Sclerostin in Postmenopausal Osteoporosis: Focus on Romosozumab and Blosozumab.

@en

P2860

Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST)

A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait

Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease

Calcium intake and risk of fracture: systematic review

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial

A 52-kb deletion in the SOST-MEOX1 intergenic region on 17q12-q21 is associated with van Buchem disease in the Dutch population

High bone density due to a mutation in LDL-receptor-related protein 5

A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density

Denosumab for prevention of fractures in postmenopausal women with osteoporosis

P2888

s40259-017-0229-2

P304

289-297

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40259-017-0229-2

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Ian Reid

P577

2017-05-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28547661

http://www.w3.org/2001/XMLSchema#string

P921

osteoporosis